SynthesisObesity surgery2026
Endoscopic Sleeve Gastroplasty versus Laparoscopic Sleeve Gastrectomy: A Systematic Review and Meta-Analysis.
Synthesis in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLaparoscopic sleeve gastrectomy (LSG) is the most common bariatric procedure worldwide, while endoscopic sleeve gastroplasty (ESG) has emerged as a less invasive alternative. This study compared their effectiveness and postoperative outcomes.
methodsA systematic search of PubMed, Scopus, and Cochrane Central was conducted up to June 2025. Non-randomized studies comparing ESG with LSG were included. Pooled odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (CIs) were pooled using random-effects models. Heterogeneity was assessed with I². Analyses were performed in R (version 4.4.2), and the risk of bias was evaluated using the ROBINS-I tool.
resultsNine studies, including 7,468 patients, were analyzed. Compared to LSG, ESG was associated with significantly lower total body weight loss (TBWL) at 6 months (MD = − 8.3%; 95% CI − 10.3 to − 6.3; p < 0.01), 1 year (MD = − 12.5%; 95% CI − 14.9 to − 10.1; p < 0.01), and 2 years (MD = − 10.2%; 95% CI − 15.3 to − 5.1; p < 0.01). ESG also showed lower excess weight loss (EWL) at 6 months (MD = − 11.6%; 95% CI − 15.3 to − 7.8; p < 0.01) and 1 year (MD = − 18.0%; 95% CI − 19.1 to − 16.8; p < 0.01), shorter hospital stay (MD = − 36.8 h; 95% CI − 66.9 to − 6.8; p = 0.02). No significant differences were found in readmissions, bleeding, or operative time.
conclusionESG achieved less weight loss than LSG but offered shorter hospitalization and comparable safety outcomes. It may serve as a less invasive alternative for selected patients.
Indexed as
Identifiers
41917549What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.